dendritic

GSK-J4 (GSK J4 HCl) is a cell permeable prodrug of GSK-J1, a dual inhibitor of the H3K27me3/me2 demethylases JMJD3/KDM6B and UTX/KDM6A (IC50=8.6/6.6 μM). GSK-J4 induces endoplasmic reticulum stress-related apoptosis.

(Z)-Leukadherin-1 (ADH-503 free base) is an allosteric agonist of CD11b.

GSK-J4 Hydrochloride (GSK J4 HCl) is a cell permeable, potent and selective histone demethylase(JMJD3 )inhibitor. is an ethyl ester derivative of the GSK-J1 with an IC50 value greater than 50 μM in vitro.

ADH-503 (GB1275) is an orally available, allosteric CD11b small molecule agonist that can lead to repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhancement of dendritic cell responses.

Immethridine dihydrobromide is a novel, highly potent and selective histamine H3 receptor (H3R) agonist that inhibits dendritic cell function and alleviates experimental autoimmune encephalomyelitis.Immethridine dihydrobromide MesV induces depolarization of neurons and the MMN and prevents cardiorenal and renal injury. injury.

GGTI 2147 FA, a selective GGT inhibitor, abolishes bicuculline-induced increase in dendritic spine density in hippocampal experiments and may reduce learning and memory abilities in mice.

3-Hydroxykynurenamine, also known as 3-Hydroxy-L-kynurenamine or 3-HKA, is a biogenic amine produced via an alternative pathway of tryptophan metabolism. In vitro, 3-HKA has an anti-inflammatory profile by inhibiting the IFN-γ mediated STAT1/NF-κΒ pathway in both mouse and human dendritic cells (DCs) with a consequent decrease in the release of pro-inflammatory chemokines and cytokines, most notably TNF, IL-6, and IL12p70. 3-HKA has protective effects in an experimental mouse model of psoriasis by decreasing skin thickness, erythema, scaling and fissuring, reducing TNF, IL-1β, IFN-γ, and IL-17 production, and inhibiting generation of effector CD8+ T cells. Similarly, in a mouse model of nephrotoxic nephritis, besides reducing inflammatory cytokines, 3-HKA improves proteinuria and serum urea nitrogen, overall ameliorating immune-mediated glomerulonephritis and renal dysfunction.This compound is unstable in powder form and other related salt forms are recommended.

G0-C14 HCl is the salt form of G0-C14, a cationic lipid molecule and amphiphilic dendritic macromolecule commonly used in the synthesis of nanoparticles and vaccine delivery.

7α,25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist, as well as an endogenous ligand, of the orphan GPCR receptor EBI2 (GPR183). It serves as a chemokine directing the migration of B cells, T cells, and dendritic cells and exhibits high potency in activating EBI2 (EC50=140 pM; Kd=450 pM) [1][2].

Resolvin E1 (RvE1) is an endogenous lipid mediator derived from the omega-3 fatty acid eicosapentaenoic acid (EPA). It exhibits anti-inflammatory properties, activates inflammation resolution, and promotes phagocytic clearance. It prevents 2,4,6-trinitrobenzenesulfonic acid-induced colitis and improves erythrocytosis and severe aplastic anaemia (SAA).

1Z105, an orally active TLR4 MD2 ligand, facilitates dendritic cell maturation and antigen presentation, thereby preventing arthritis.

NOD2 agonist 2 (compound 23) enhances antigen presentation in murine bone marrow-derived dendritic cells (BMDCs), highlighting its potential as a vaccine adjuvant.

Perfluoroenanthic acid (Perfluoroheptanoic acid) is a perfluoroalkyl substance (PFAS) that negatively impacts spermatogenic development and testicular m6A RNA methylation in offspring exposed during gestation, thus impeding spermatogenesis and inducing reproductive toxicity. Additionally, in primary cortical neuron cultures, Perfluoroenanthic acid alters dendritic spine morphology and synaptogenesis, enhances neural activity and synaptic transmission, and increases the expression of excitatory synapse-associated proteins Synaptophysin and PSD95.

Apilimod (STA 5326) inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.

Lipid N2-3L is an ionizable cationic lipid with a pKa of 8.99, utilized in the formation of supramolecular lipid nanoparticles (SMLNPs) for enclosing mRNA in both in vitro and in vivo applications. Lipid N2-3L-containing SMLNPs accumulate at the injection site and draining lymph nodes in mice, featuring a luciferase reporter gene. Additionally, SMLNPs made with Lipid N2-3L that encapsulate ovalbumin mRNA and the Toll-like receptor 7 8 (TLR7 8) agonist R-848 serve as adjuvants. These enhance dendritic cell maturation and antigen presentation, reducing tumor volume and increasing survival rates in MC-38-OVA colon cancer mouse models.

Calcium influx inducer compound 634 is an agent that stimulates calcium entry. At a concentration of 10 µM, it can enhance the release of extracellular vesicles (EVs) from mouse bone marrow-derived dendritic cells (mBMDCs). Furthermore, Calcium influx inducer compound 634 (10 µM) increases the levels of surface CD86 and CD80 on mBMDCs, an effect that can be blocked by the calcium release-activated calcium channel inhibitor YM-58483.

9-Methyl-β-carboline is a cognitive enhancer with neuroprotective, neurorestorative, and anti-inflammatory properties. Its behavioral effects may be linked to hippocampal dopamine levels and the stimulation of dendritic and synaptic proliferation.

ISM012-042 is an orally active inhibitor of PHD1 and PHD2, with IC50 values of 1.9 and 2.5 nM, respectively. At a concentration of 2.5 μM, ISM012-042 protects Caco-2 cells from DSS-induced barrier damage. Additionally, in LPS-induced bone marrow-derived dendritic cells (BMDC) from mice, ISM012-042 exhibits anti-inflammatory properties by dose-dependently reducing the expression of IL-12 subunit IL-12p35 and TNF. It also restores intestinal barrier function and alleviates intestinal inflammation in various experimental colitis models. ISM012-042 is useful for studying intestinal mucosal repair and immune disorders.

VB-85247 is a STING agonist that, by activating the STING pathway, induces the upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, as well as the maturation and activation of dendritic cells. It can lead to the regression of tumors within the bladder and is applicable in bladder cancer research.

BRI-50460 is an inhibitor of cytosolic calcium-dependent phospholipase A2 (cPLA2) with the ability to cross the blood-brain barrier, exhibiting an IC50 of 0.88 nM. By inhibiting cPLA2, BRI-50460 modulates downstream inflammatory lipid signaling pathways, mitigating the effects of amyloid β42 oligomers on cPLA2 activation, tau protein hyperphosphorylation, and synaptic and dendritic loss. This results in its activity in regulating neuroinflammation and restoring lipid homeostasis. BRI-50460 is applicable in research related to Alzheimer's disease and other neurodegenerative disorders.

DDC18-8A is an amphiphilic dendritic polymer known for its potent antimicrobial and antibiofilm properties.

PAD4-IN-4 (compound 28) is a potent PAD4 inhibitor with an IC50 of 0.79±0.09 μM. It reshapes the neutrophil phenotype, increases the proportion of dendritic cells and M1 macrophages, reduces the number of myeloid-derived suppressor cells, and enhances the tumor immune microenvironment. PAD4-IN-4 is applicable for research in triple-negative breast cancer.

BIT225 is a human immunodeficiency virus type 1 Vpu inhibitor with antiviral activity that inhibits HIV-1 replication in bone marrow dendritic cells and inhibits ion channels formed by HIV-1 Vpu.

CM-414 is a dual inhibitor of HDACs and PDE5 for the Treatment of Alzheimer's Disease (IC50 values of 60 nM, 310 nM, 490 nM, 322 nM, and 91 nM against PDE5, HDAC1, HDAC2, HDAC3, and HDAC6, respectively). Chronic treatment of Tg2576 mice with CM-414 dimini